BY ALBERT RONNING-ANDERSSON
-
Crucial quarter for Genmab: J&J must decide on “miracle drug”
Genmab CEO Jan van de Winkel says there are other options if the deal falls through.
-
Novo Nordisk achieves weight loss of just over 20% with high-dose version of semaglutide
Around 33% of high-dose individuals accomplished a weight-loss of 25% or even more.
-
Novo Holdings-owned Sonion settles IP violation case with Sony and Huawai
” Economically, we really did not anticipate to be far better off by winning the primary situation,” states the chief executive officer.
-
Evaxion has all patients lined up for Phase 2 trial with lead candidate
The schedule is thereby on track, and data is expected to continue to arrive in the second half of 2025.
-
Novo Nordisk’s obesity and diabetes drugs part of upcoming US price negotiations
The discussed rates for the following 15 medications will certainly enter result on Jan. 1, 2027.
-
New York-based obesity biotech startup files for IPO in the US
Less than a year after its founding, US-based Metsera has filed for an initial public offering to accelerate the development of a its long-acting injectable GLP-1 agonist.
-
Leo Pharma in billion-dollar deal with US pharmaceutical giant
The cope with US-based Gilead Sciences offers Leo Pharma an instantaneous cost of simply over USD 246m, whereas the whole worth may quantity to USD 1.7bn. To this have to be added …
-
Novo Nordisk starts weight-loss collaboration with US biotech company
The arrangement sets you back Novo Nordisk approximately USD 50m in ahead of time repayment and r & d financing. On top of that, there are alternative and turning point settle…
-
EU Commission to allow electronic instructions for use of medical devices
A fantastic success for the sector, states Medicoindustrien.
-
GSK receives Chinese approval for chronic rhinosinusitis treatment
The British firm currently has actually 3 accepted signs for the medication mepolizumab in China.
